Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.45 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677838 | 0.95 | HCAR3 (0.49) | HCAR3BAZ2BEPHX2L3MBTL1 | |
| SCHEMBL32677808 | 0.82 | HCAR3 (0.42) | HCAR3NNMTBAZ2B | |
| SCHEMBL29829392 | 0.81 | NPC1 (0.52) | L3MBTL1 | |
| SCHEMBL29666324 | 0.81 | NPC1 (0.52) | L3MBTL1 | |
| SCHEMBL27874609 | 0.81 | HCAR3 (0.69) | HCAR3 | |
| SCHEMBL28157252 | 0.80 | NNMT (0.70) | HCAR3NNMTEPHX2L3MBTL1 | |
| SCHEMBL19736133 | 0.78 | PTK2 (0.57) | HCAR3NNMTBAZ2B | |
| SCHEMBL31017395 | 0.77 | MAP4K1 (0.47) | — | |
| SCHEMBL31017468 | 0.77 | MAP4K1 (0.47) | — | |
| SCHEMBL31017485 | 0.77 | MAP4K1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | claimed |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LTD (GB) | 2026-02-26 | — | — | US | disclosed |
| CN-117242072-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2023-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | HCAR3 2585/4885NNMT 838/4885BAZ2B 78/4885 |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, CSNK2A3, CSNK2B | HCAR3 1546/4885NNMT 1960/4885BAZ2B 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.